Your browser doesn't support javascript.
loading
External validation of the PROGRESS-CTO perforation risk score: Individual patient data pooled analysis of three registries.
Simsek, Bahadir; Tajti, Peter; Carlino, Mauro; Ojeda, Soledad; Pan, Manuel; Rinfret, Stephane; Vemmou, Evangelia; Kostantinis, Spyridon; Nikolakopoulos, Ilias; Karacsonyi, Judit; Rempakos, Athanasios; Dens, Joseph A; Agostoni, Pierfrancesco; Alaswad, Khaldoon; Megaly, Michael; Avran, Alexandre; Choi, James W; Jaffer, Farouc A; Doshi, Darshan; Karmpaliotis, Dimitri; Khatri, Jaikirshan J; Knaapen, Paul; La Manna, Alessio; Spratt, James C; Tanabe, Masaki; Walsh, Simon; Mastrodemos, Olga C; Allana, Salman; Rangan, Bavana V; Goktekin, Omer; Gorgulu, Sevket; Poommipanit, Paul; Kearney, Kathleen E; Lombardi, William L; Grantham, J Aaron; Mashayekhi, Kambis; Brilakis, Emmanouil S; Azzalini, Lorenzo.
Afiliação
  • Simsek B; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Tajti P; The Gottsegen National Cardiovascular Center, Budapest, Hungary.
  • Carlino M; Interventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.
  • Ojeda S; Division of Interventional Cardiology, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.
  • Pan M; Division of Interventional Cardiology, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.
  • Rinfret S; Emory Heart and Vascular Center, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Vemmou E; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Kostantinis S; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Nikolakopoulos I; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Karacsonyi J; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Rempakos A; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Dens JA; Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
  • Agostoni P; Hartcentrum, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium.
  • Alaswad K; Henry Ford Health System, Detroit, Michigan, USA.
  • Megaly M; Division of Cardiology, Willis Knighton Heart Institute, Shreveport, Louisiana, USA.
  • Avran A; Department of Interventional Cardiology, Clinique Pasteur, Essey-lès-Nancy, Toulouse, France.
  • Choi JW; Division of Cardiology, Texas Health Presbyterian Hospital, Dallas, Texas, USA.
  • Jaffer FA; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Doshi D; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Karmpaliotis D; Morristown Medical Center, Morristown, New Jersey, USA.
  • Khatri JJ; Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Knaapen P; Department of Cardiology, VU University Medical Center, Amsterdam, the Netherlands.
  • La Manna A; University of Catania, Catania, Italy.
  • Spratt JC; St. George's University Healthcare NHS Trust, London, UK.
  • Tanabe M; Department of Cardiology, Nozaki Tokushukai Hospital, Osaka, Japan.
  • Walsh S; Belfast Health, Belfast, UK.
  • Mastrodemos OC; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Allana S; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Rangan BV; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
  • Goktekin O; Division of Cardiology, Memorial Bahcelievler Hospital, Istanbul, Turkey.
  • Gorgulu S; Division of Cardiology, Biruni University School of Medicine, Istanbul, Turkey.
  • Poommipanit P; University Hospitals, Cleveland, Ohio, USA.
  • Kearney KE; Division of Cardiology, University of Washington, Seattle, Washington, USA.
  • Lombardi WL; Division of Cardiology, University of Washington, Seattle, Washington, USA.
  • Grantham JA; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
  • Mashayekhi K; Division of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany.
  • Brilakis ES; Department for Internal Medicine and Cardiology, Heart center Lahr, Lahr, Germany.
  • Azzalini L; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
Article em En | MEDLINE | ID: mdl-36617391
ABSTRACT

BACKGROUND:

Coronary artery perforation is one of the most feared and common complications of chronic total occlusion (CTO) percutaneous coronary intervention (PCI).

METHODS:

To assess the usefulness of the recently developed PROGRESS-CTO (NCT02061436) perforation risk score in independent cohorts. Individual patient-level data pooled analysis of three registries was performed.

RESULTS:

Of the 4566 patients who underwent CTO PCI at 25 centers, 196 (4.2%) had coronary artery perforation. Patients with perforations were older (69 ± 10 vs. 65 ± 10, p < 0.001), more likely to be women (19% vs. 13%, p = 0.009), more likely to have a history of prior coronary artery bypass graft (34% vs. 20%, p < 0.001), and unfavorable angiographic characteristics such as blunt stump (62% vs. 48%, p < 0.001), proximal cap ambiguity (52% vs. 34%, p < 0.001), and moderate-severe calcification (60% vs. 49%, p = 0.002). Technical success was lower in patients with perforations (73% vs. 88%, p < 0.001). The area under the receiver operating characteristic curve of the PROGRESS-CTO perforation risk model was 0.76 (95% confidence interval [CI], 0.72-0.79), with good calibration (Hosmer-Lemeshow p = 0.97). We found that the CTO PCI perforation risk increased with higher PROGRESS-CTO perforation scores 0.3% (score 0), 2.3% (score 1), 3.1% (score 2), 5.5% (score 3), 7.5% (score 4), 14.6% (score 5).

CONCLUSION:

Given the good discriminative performance, calibration, and the ease of calculation, the PROGRESS-CTO perforation score may facilitate assessment of the risk of perforation in patients undergoing CTO PCI.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Catheter Cardiovasc Interv Assunto da revista: CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Catheter Cardiovasc Interv Assunto da revista: CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos